Exoprobes srl

Exoprobes’ LB platform performs early diagnostic of Neurodegenerative diseases increasing patient’s quality of life allowing specific and timely treatments

  • Stage Product In Development
  • Industry Biotechnology
  • Location Bologna, Metropolitan City of Bologna, Italy
  • Currency EUR
  • Founded June 2020
  • Employees 1
  • Incorporation Type Not Incorporated
  • Website exoprobes.it

Company Summary

Neurodegenerative diseases diagnosis often happens too late.
+10 million people in the world suffer of Parkinson’s disease and this number is predicted to redouble by 2030. Exoprobes is developing a unique early diagnosis platform for Neurodegenerative disease, Simple and Specific Blood & Saliva based liquid biopsy. Exoprobes’ test platform performs early diagnostic of Neurodegenerative disease before symptoms arise

Team

  • Silvestro Turtoro
    Founder & CEO

  • Guido Frigieri
    COO

  • Oreste D'Ambrosio
    CFO

  • Alessandro Bortolani
    Biz Developer

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free